HC Wainwright started coverage on shares of FibroBiologics (NASDAQ:FBLG - Free Report) in a report released on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $12.00 price objective on the stock.
Several other equities analysts have also recently issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a "strong-buy" rating in a research note on Wednesday, September 4th. Maxim Group assumed coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a "buy" rating and a $12.00 target price on the stock.
Get Our Latest Analysis on FBLG
FibroBiologics Trading Up 7.3 %
Shares of FibroBiologics stock traded up $0.20 during trading on Wednesday, hitting $2.95. 242,492 shares of the company's stock were exchanged, compared to its average volume of 260,260. FibroBiologics has a 52-week low of $1.08 and a 52-week high of $55.00. The business has a 50-day simple moving average of $2.63 and a 200-day simple moving average of $5.53.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Equities research analysts predict that FibroBiologics will post -0.37 earnings per share for the current year.
Institutional Investors Weigh In On FibroBiologics
A number of institutional investors have recently added to or reduced their stakes in FBLG. Mercer Global Advisors Inc. ADV purchased a new stake in FibroBiologics during the 2nd quarter worth approximately $51,000. Cahaba Wealth Management Inc. purchased a new stake in shares of FibroBiologics during the second quarter worth approximately $73,000. Saxon Interests Inc. purchased a new position in FibroBiologics in the 2nd quarter valued at $106,000. Rhumbline Advisers acquired a new stake in FibroBiologics during the 2nd quarter worth $115,000. Finally, Symphony Financial Ltd. Co. purchased a new stake in shares of FibroBiologics during the third quarter worth $76,000.
FibroBiologics Company Profile
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Read More
Before you consider FibroBiologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroBiologics wasn't on the list.
While FibroBiologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
